FDA taking hard look at 30 compounding pharmacies

The FDA is forging ahead with oversight of some large compounding pharmacies, targeting 30 "high risk" compounders for inspections over the next two months. An FDA spokeswoman told Bloomberg the inspections started Feb. 19 and focus on compounders that make sterile injectable drugs. It was that kind of large-scale compounder, New England Compounding Center, whose products are tied to last year's deadly meningitis outbreak. Story | More